|Day Low/High||161.47 / 166.36|
|52 Wk Low/High||74.37 / 170.05|
Focus on coronavirus patients has hospitals deferring elective surgeries, but eventually patients who need knee, hip and other replacements will be back on surgical schedules.
Straying from these names could land you in quicksand as the 4th quarter begins.
Analyst downgrades and mind-boggling P/E ratios do not matter in this current market.
Demand for artificial joints is growing, and Zimmer Biomet is a good way to play the demographic trend.
We know that we are in the era when index managers are ascendant.
Here's a rundown of four technical setups that are showing solid trading potential.
These companies show signs of a change of direction.
If prices continue higher they are likely to encounter resistance above $120.
The medical device maker expects sales of $2 billion in the fourth quarter, topping Wall Street expectations of $1.97 billion.
Current valuations are at record lows, despite the companies having good prospects.
Investors shouldn't be buying certain healthcare stocks based on Donald Trump's nomination of Tom Price as HHS chief, says Jim Cramer.
Shares are trading at less than 12.5x 2017's EPS estimates and should rise soon.
Today there was a virtual vacuum of good news in the stock market.
We have to ask: where is the cash flow to pay off the debt, if any important prices are rolled back?
Shares of Zimmer Biomet were under pressure Monday after cutting its full-year forecast.
Here's a window into what institutional investors may be doing and how to profit from that.
Analyst action changes the outlook for the oil industry, while shareholders are running from Nike.
Look out below when it comes to margins, as the price wars extend to sneakers, drugs and others.
But several airline and retail stocks are proving highly volatile.
When KKR and Apollo sell a stock it should be a huge red flag to investors to consider following suit.
Names that shareholders should watch are those where PE firms hold big stakes in their companies.
Medical technology companies are hot and not even climbing price-to-earnings multiples will slow down the likes of Hologic, Zimmer Biomet, Zeltiq and NuVasive.
Zimmer Biomet is on track to return to growth, which could signal more mergers and acquisitions within the industry.